People usually search for this
TB-500 10mg
$90.00
≥99% purity · HPLC verified · MS confirmed
How we test →
Products will arrive in a lyophilized (powder) form for maximum stability
TB-500 is a synthetic 17-amino acid fragment of Thymosin Beta-4 representing the active actin-binding region. Preclinical research has documented effects on cell migration, wound healing, cardiac repair, and tissue regeneration across multiple injury models. Supplied as a 10mg lyophilized vial at ≥99% HPLC purity, for research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
TB-500 (Ac-Tβ4(17–23))
SYNONYMS
TB500, 885340-08-9, UNII-QHK6Z47GTG, QHK6Z47GTG, TB-500
CAS NUMBER
77591-33-4
MOLECULAR FORMULA
C212H350N56O78S
MOLECULAR WEIGHT
~4963 g/mol
STRUCTURE
Synthetic acetylated 7-amino acid peptide derived from Tβ4
PEPTIDE SEQUENCE
Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH
CHEMICAL STRUCTURE
Molecular Formula: C212H350N56O78S
Source: PubChem
Mechanism of Action
TB-500 mimics the bioactive region of thymosin β4, interacting with actin monomers to regulate the cytoskeleton1. It promotes cell migration, angiogenesis, and wound re-epithelialization. Research suggests TB-500’s effects may also be mediated through its metabolite Ac-LKKTE2,3.
Biological Activity
Demonstrates potent pro-regenerative, pro-angiogenic, and anti-inflammatory properties. TB-500 enhances keratinocyte and fibroblast migration, accelerates dermal healing, and supports vascularization in injured tissues without cytotoxicity1-4.
Storage
- Store lyophilized powder at –20°C. Reconstituted solutions should be stored at 2–8°C and used within 30 days.
Drug Categories
Peptide therapeutic, wound healing agent, angiogenesis modulator
Additional Notes
- Under investigation for use in cardiac, corneal, and dermal tissue repair.
- Subject to anti-doping regulations due to performance-enhancing properties.
Summary Table
Property
Description
CAS Number
77591-33-4
Molecular Formula
C212H350N56O78S
Molecular Weight (MW)
4963.0 g/mol
Mechanism of Action
Mimics Tβ4, promotes actin polymerization
Biological Activity
Enhances wound healing and angiogenesis
Supplied Form
Lyophilized powder
Purity
≥99% (HPLC)
Storage
–20°C (powder); 2–8°C (solution)
Drug Categories
Actin modulator; angiogenic peptide
Additional Notes
Investigational agent; banned in competitive sports
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
TB-500 is a synthetic peptide designed to replicate the wound healing and regenerative functions of thymosin β4. Composed of seven amino acids, TB-500 corresponds to the bioactive region (LKKTETQ) of thymosin β4, with an N-terminal acetylation to improve stability and bioavailability. Studies suggest that TB-500 plays a key role in modulating actin polymerization, thereby supporting cytoskeletal reorganization during tissue repair. It has shown effectiveness in models of corneal, dermal, and cardiac injuries1,3,4. In vitro and in vivo research has demonstrated that TB-500 and its metabolites are non-cytotoxic, with the Ac-LKKTE metabolite particularly enhancing fibroblast-driven wound closure. TB-500 continues to be of interest in regenerative medicine research, despite its inclusion on the World Anti-Doping Agency’s prohibited list.
Research Highlights
Promotes dermal and tendon healing via fibroblast recruitment3
Promotes blood vessel formation, aiding ischemic tissue recovery4
Modulates cytoskeletal remodeling critical for cell migration and repair1
Demonstrated safety in cellular assays across multiple tissues.
2
Ac-LKKTE, a TB-500 metabolite, exhibits superior activity in promoting wound closure compared to the parent compound3.
Pharmacokinetic Profile
Route of Administration
Subcutaneous
- Route of Administration: subcutaneous (experimental)
- Half-Life: Short (~30-90 min); dependent on route and formulation
- Formulation: Lyophilized powder for reconstitution
Formulation & Handling
- Lyophilized peptide powder, reconstituted in sterile PBS or water.
- Store lyophilized form at –20 °C; Store reconstituted solution at 2-8°C and use within 30 days.
- Avoid repeated freeze–thaw cycles.
Clinical Trial Activity
Trial ID
Title
Phase
Study Type
Sponsor
NCT05555589
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
3
Interventional
ReGenTree, LLC
References
1
Treadwell, T., Kleinman, H. K., Crockford, D., Hardy, M. A., Guarnera, G. T. & Goldstein, A. L. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann. N. Y. Acad. Sci. 1270, 37–44 (2012).
2
Rahaman, K. A. et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J. Chromatogr. B 1235, 124033 (2024).
3
Maar, K. et al. Utilizing developmentally essential secreted peptides such as thymosin beta-4 to remind the adult organs of their embryonic state—new directions in anti-aging regenerative therapies. Cells 10, 1343 (2021).
4
Sosne, G. et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp. Eye Res. 74, 293–299 (2002).
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart You may also like…
BPC-157/TB-500 10+10mg
Summary Description: BPC-157 and TB-500 is an investigational blend of two well-studied peptides known for their regenerative and cytoprotective properties. BPC-157, derived from a gastric protein, is recognized for promoting angiogenesis, cellular migration, and tissue healing across various organ systems1,2. TB-500, a synthetic fragment of thymosin beta-4, enhances cellular motility, reduces inflammation, and stimulates new blood vessel formation3,4. Together, this synergistic blend is being explored in preclinical research for its ability to accelerate wound healing, mitigate inflammation, and enhance recovery in models of soft tissue injury, nerve damage, and musculoskeletal trauma. While individually effective, the co-administration of BPC-157 and TB-500 may produce more robust regenerative outcomes by targeting both the structural and signaling components of tissue repair.
Products will arrive in a lyophilized (powder) form for maximum stability
Related products
GHK-Cu 50mg
Summary Description: GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It has potent tissue remodeling, wound healing, antioxidant, and anti-inflammatory properties. GHK-Cu stimulates collagen and glycosaminoglycan synthesis, modulates inflammation, promotes angiogenesis, and supports tissue regeneration and repair. It has been widely studied for applications in dermatology, regenerative medicine, and aging-related research for its role in tissue rejuvenation and healing1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 10mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 5mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
NAD+ 500mg
Summary Description: Nicotinamide adenine dinucleotide (NAD?) is a ubiquitous pyridine nucleotide coenzyme present in all living cells. It serves critical roles in cellular redox reactions for energy metabolism and acts as an essential substrate for key signaling enzymes regulating DNA repair, gene expression, and cell signaling. Cellular NAD? levels influence metabolic health, stress response, and tissue regeneration1,3.
Products will arrive in a lyophilized (powder) form for maximum stability
PT-141 10mg
Summary Description: PT-141 is a synthetic cyclic heptapeptide derivative of alpha-melanocyte stimulating hormone (?-MSH), designed to act as a potent and selective melanocortin receptor agonist, particularly at MC3 and MC4. It is primarily researched for its unique ability to induce sexual arousal and enhance sexual function in both men and women without acting via direct hormonal or vascular mechanisms. PT-141 is supplied strictly for laboratory research use1,2,4.
Products will arrive in a lyophilized (powder) form for maximum stability
Retatrutide 10mg
Summary Description: Retatrutide is a next-generation investigational medication initially developed for the treatment of obesity and type 2 diabetes, with emerging evidence highlighting its potential multi-system benefits. Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist. This means it simultaneously activates the receptors for GIP, glucagon-like peptide-1 (GLP-1), and glucagon. Through this triple-receptor agonism, retatrutide not only lowers blood glucose levels and enhances insulin sensitivity but also suppresses appetite, increases energy expenditure, and reduces body weight. Early clinical studies suggest that retatrutide may improve cardiometabolic profiles by reducing blood pressure and improving lipid levels, further underscoring its promise for addressing both metabolic and cardiovascular risk factors in individuals with obesity and diabetes.
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 15mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4
Products will arrive in a lyophilized (powder) form for maximum stability